Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Targeted Delivery for Oligonucleotide Molecular Therapeutics

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma

Nonviral delivery systems for antisense oligonucleotide therapeutics

The application of antisense oligonucleotides in disease treatment

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy

Antisense Oligonucleotide-Based Therapy of Viral Infections

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

Antisense oligonucleotides: a novel Frontier in pharmacological strategy

High-Resolution Visualisation of Antisense Oligonucleotide Release from Polymers in Cells

Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights

NIR light-controlled DNA nanodevice for amplified mRNA imaging and precise gene therapy

Antitumoral RNA‐targeted oligonucleotide therapeutics: the third pillar after small molecule inhibitors and antibodies

Thermodynamic and cellular studies of doxorubicin/daunorubicin loaded by a DNA tetrahedron for diagnostic imaging, chemotherapy, and gene therapy

Noninvasive Delivery of Oligonucleotide by Penetratin-Modified Polyplexes to Inhibit Protein Expression of Intraocular Tumor

Nanodelivery Systems Delivering Hypoxia-Inducible Factor-1 Alpha Short Interfering RNA and Antisense Oligonucleotide for Cancer Treatment

Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma

Theranostic DNA nanostructure based on phenotype-specific activation of antisense oligonucleotides